The estimated Net Worth of Michael W. Lark is at least $750 mil dollars as of 10 February 2017. Michael Lark owns over 23,699 units of Trevena Inc stock worth over $559,960 and over the last 11 years Michael sold TRVN stock worth over $189,592.
Michael has made over 2 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Michael sold 23,699 units of TRVN stock worth $189,592 on 10 February 2017.
The largest trade Michael's ever made was selling 23,699 units of Trevena Inc stock on 10 February 2017 worth over $189,592. On average, Michael trades about 3,587 units every 99 days since 2014. As of 10 February 2017 Michael still owns at least 74,761 units of Trevena Inc stock.
You can see the complete history of Michael Lark stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA, PA, 19406.
Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire, ePartners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Trevena Inc executives and other stock owners filed with the SEC include: